[44] Comparative Efficacy Comorbidity-Specific Drug Selection Cardiovascular and Renal Outcomes Semaglutide reduced major adverse cardiovascular events in SELECT among adults with established cardiovascular disease and overweight or obesity without diabetes, with a hazard ratio of 0.80 for the primary 3-point MACE outcome
Cancer Intravenous vitamin C can be used in high doses to fight cancer in tandem with traditional chemotherapy
Before I used to have up to 8 coffees a day with 2 sweets, I'm less attracted to sugar now I have 3 with 1 sugar Sandrine Fellak - Glucose Support Capsules As a vegetarian sportsman for more than thirty years, I was lacking a powerful anti inflammatory to improve my health
Semaglutide was originally developed by Novo Nordisk as an antidiabetic agent under the brand name Ozempic (0.52 mg weekly, subcutaneous), approved by the FDA in 2017 for type 2 diabetes management
Liu Zhaozhao (90) reported that liraglutide can activate GLP-1Rs, and that liraglutide can promote the proliferation of breast cancer cells by activating GLP-1Rs
Liu CY, Xiao YZ, Li RS, Li XR, Yuan HL